{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:07:12Z","timestamp":1782727632480,"version":"3.54.5"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The recombinant zoster vaccine (RZV) is immunologically and clinically effective in immunosuppressed patients. Though rheumatoid arthritis (RA) and the Janus kinase inhibitor (JAKi) increase the risk of herpes zoster (HZ) infection, breakthrough cases in which a HZ infection followed RZV administration are rare. We report herein a 63-year-old female patient with seropositive RA who experienced a HZ infection despite receiving the RZV. She had been receiving tocilizumab, methotrexate, and low-dose prednisolone until tocilizumab was switched to upadacitinib 4 weeks after two RZV administrations, which resulted in 63\u2009weeks\u2019 remission. Her current admission was for a painful rash consisting of blisters and erythema on the right nasal alar and lips corresponding to the right V2 segment of the trigeminal nerve. HZ was diagnosed and treated for 7 days with intravenous acyclovir, which alleviated the symptoms. JAKi can suppress a range of immunogenic mechanisms which underlie the efficacy of the RZV. The present patient was expected to respond favourably to the RZV because JAKi had not been administered prior to the vaccinations; however, the later start of JAKi therapy caused a breakthrough HZ infection. Immunocompromised patients have a higher risk of severe HZ, including the disseminated form, but breakthrough cases are relatively rare. The RZV is recommended as prophylaxis against HZ as well as means of mitigating its severity when it does occur.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf012","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T23:22:22Z","timestamp":1738624942000},"source":"Crossref","is-referenced-by-count":4,"title":["Breakthrough herpes zoster following recombinant zoster vaccinations in a rheumatoid arthritis patient receiving a Janus kinase inhibitor: A case report and literature review"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7162-1276","authenticated-orcid":false,"given":"Shunya","family":"Nagata","sequence":"first","affiliation":[{"name":"Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-443X","authenticated-orcid":false,"given":"Naoto","family":"Yokogawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"2026011607365775400_R1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.55563\/clinexprheumatol\/cpu6r9","article-title":"Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review","volume":"40","author":"Winthrop","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026011607365775400_R2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.idc.2017.07.016","article-title":"Herpes zoster in the older adult","volume":"31","author":"John","year":"2017","journal-title":"Infect Dis Clin North Am"},{"key":"2026011607365775400_R3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/gerona\/gly150","article-title":"Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older","volume":"74","author":"Curran","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026011607365775400_R4","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"2026011607365775400_R5","doi-asserted-by":"crossref","first-page":"e00240","DOI":"10.1128\/JVI.00240-21","article-title":"Comparative antibody responses to the live-attenuated and recombinant herpes zoster vaccines","volume":"95","author":"Schmid","year":"2021","journal-title":"J Virol"},{"key":"2026011607365775400_R6","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI121484","article-title":"Th1 memory differentiates recombinant from live herpes zoster vaccines","volume":"128","author":"Levin","year":"2018","journal-title":"J Clin Invest"},{"key":"2026011607365775400_R7","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2026011607365775400_R8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2026011607365775400_R9","article-title":"Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026011607365775400_R10","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/infdis\/jiaa300","article-title":"Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination","volume":"224","author":"Hastie","year":"2021","journal-title":"J Infect Dis"},{"key":"2026011607365775400_R11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res"},{"key":"2026011607365775400_R12","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology"},{"key":"2026011607365775400_R13","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/rheumatology\/kead552","article-title":"Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinas","volume":"63","author":"K\u00e4llmark","year":"2024","journal-title":"Rheumatology"},{"key":"2026011607365775400_R14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24086967","article-title":"Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: a prospective observational study","volume":"24","author":"Venerito","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026011607365775400_R15","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2024-eular.2950","article-title":"POS1476-HPR the adjuvanted recombinant zoster vaccine is effective in patients \u226550 years of age with rheumatoid arthritis at increased risk of herpes zoster: results from a real-world database analysis in the United States from 2018 to 2021","volume":"83","author":"Constenla","year":"2024","journal-title":"Ann Rheumatic Dis"},{"key":"2026011607365775400_R16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","article-title":"Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register","volume":"81","author":"Redeker","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026011607365775400_R17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center\u2019s experience with 400 patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2026011607365775400_R18","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2023-eular.1013","article-title":"AB1774-HPR safety of the recombinant herpes zoster vaccine in patients with rheumatoid arthritis treated with jaki drugs","volume":"82","author":"Pons-Bas","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"2026011607365775400_R19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00296-022-05270-6","article-title":"Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies","volume":"43","author":"Gialouri","year":"2023","journal-title":"Rheumatol Int"},{"key":"2026011607365775400_R20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cei\/uxad033","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications","volume":"213","author":"Seida","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"2026011607365775400_R21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000522272","article-title":"Reactivation of herpes zoster keratitis following shingrix vaccine","volume":"13","author":"Lu","year":"2022","journal-title":"Case Rep Ophthalmol"},{"key":"2026011607365775400_R22","article-title":"Varicella: Chapter 17","author":"Manual for the Surveillance of Vaccine-Preventable Disease"},{"key":"2026011607365775400_R23","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine breakthrough infections with SARS-CoV-2 variants","volume":"384","author":"Hacisuleyman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026011607365775400_R24","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S1473-3099(21)00558-2","article-title":"Hospitalisation among vaccine breakthrough COVID-19 infections","volume":"21","author":"Juthani","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026011607365775400_R25","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/s41591-022-01840-0","article-title":"Long COVID after breakthrough SARS-CoV-2 infection","volume":"28","author":"Al-Aly","year":"2022","journal-title":"Nat Med"},{"key":"2026011607365775400_R26","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/art.40187","article-title":"The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026011607365775400_R27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J Rheumatol"},{"key":"2026011607365775400_R28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/mr\/roac029","article-title":"Impact of Janus kinase inhibitors on antibody response to 13-valent pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"33","author":"Mori","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026011607365775400_R29","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNgamma response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"key":"2026011607365775400_R30","doi-asserted-by":"crossref","DOI":"10.3390\/biom14070739","article-title":"Exploring the link between varicella-zoster virus, autoimmune diseases, and the role of recombinant zoster vaccine","volume":"14","author":"Ishihara","year":"2024","journal-title":"Biomolecules"},{"key":"2026011607365775400_R31","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026011607365775400_R32","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13154423","article-title":"Turning the tide against herpes zoster in rheumatoid arthritis patients treated with JAK inhibitors","volume":"13","author":"Cito","year":"2024","journal-title":"J Clin Med"},{"key":"2026011607365775400_R33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1080\/21645515.2018.1560918","article-title":"Immune responses to zoster vaccines","volume":"15","author":"Levin","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2026011607365775400_R34","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"key":"2026011607365775400_R35","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/rheumatology\/keac365","article-title":"Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis","volume":"62","author":"Monti","year":"2023","journal-title":"Rheumatology"},{"key":"2026011607365775400_R36","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1016\/j.vaccine.2023.07.052","article-title":"Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis","volume":"41","author":"Hamad Saied","year":"2023","journal-title":"Vaccine"},{"key":"2026011607365775400_R37","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026011607365775400_R38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2026011607365775400_R39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026011607365775400_R40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","article-title":"Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers","volume":"65","author":"Fomin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2026011607365775400_R41","first-page":"952","article-title":"Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone","volume":"34","author":"Visvanathan","year":"2007","journal-title":"J Rheumatol"},{"key":"2026011607365775400_R42","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1016\/j.vaccine.2017.07.094","article-title":"Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study","volume":"35","author":"Grabar","year":"2017","journal-title":"Vaccine"},{"key":"2026011607365775400_R43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40261-024-01355-1","article-title":"Differential utility losses in herpes zoster cases between vaccinated and unvaccinated subjects: a meta-analysis of three clinical trials","volume":"44","author":"Giannelos","year":"2024","journal-title":"Clin Drug Investig"},{"key":"2026011607365775400_R44","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29911","article-title":"The effect of recombinant zoster vaccine on patients with chronic obstructive pulmonary diseases: a multi-institutional propensity score-matched cohort study","volume":"96","author":"Tsai","year":"2024","journal-title":"J Med Virol"},{"key":"2026011607365775400_R45","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026011607365775400_R46","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/j.pain.0000000000002760","article-title":"Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials","volume":"164","author":"Kim","year":"2023","journal-title":"Pain"},{"key":"2026011607365775400_R47","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2263979","article-title":"Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence","volume":"19","author":"Parikh","year":"2023","journal-title":"Hum Vaccin Immunother"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf012\/61746296\/rxaf012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf012\/61746296\/rxaf012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf012\/61746296\/rxaf012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:37:10Z","timestamp":1768567030000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf012\/7997958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf012","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf012"}}